GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Inventiva SA (XPAR:IVA) » Definitions » Net Cash per Share

Inventiva (XPAR:IVA) Net Cash per Share : €-2.07 (As of Jun. 2024)


View and export this data going back to 2017. Start your Free Trial

What is Inventiva Net Cash per Share?

Net Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities minus Total Liabilities minus Minority Interest and then divided by Shares Outstanding (EOP). Inventiva's Net Cash per Share for the quarter that ended in Jun. 2024 was €-2.07.

The historical rank and industry rank for Inventiva's Net Cash per Share or its related term are showing as below:

During the past 11 years, the highest Price-to-Net-Cash Ratio of Inventiva was 13.83. The lowest was 1.75. And the median was 5.13.

XPAR:IVA's Price-to-Net-Cash is not ranked *
in the Biotechnology industry.
Industry Median: 4.27
* Ranked among companies with meaningful Price-to-Net-Cash only.

Inventiva Net Cash per Share Historical Data

The historical data trend for Inventiva's Net Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Inventiva Net Cash per Share Chart

Inventiva Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net Cash per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.66 2.21 1.52 0.41 -1.43

Inventiva Semi-Annual Data
Dec13 Dec14 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Net Cash per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.15 0.41 -1.12 -1.43 -2.07

Competitive Comparison of Inventiva's Net Cash per Share

For the Biotechnology subindustry, Inventiva's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Inventiva's Price-to-Net-Cash Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Inventiva's Price-to-Net-Cash distribution charts can be found below:

* The bar in red indicates where Inventiva's Price-to-Net-Cash falls into.



Inventiva Net Cash per Share Calculation

In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.

Inventiva's Net Cash per Share for the fiscal year that ended in Dec. 2023 is calculated as

Net Cash per Share (A: Dec. 2023 )
=(Cash, Cash Equivalents, Marketable Securities-Total Liabilities-Minority Interest)/Shares Outstanding (EOP)
=(26.988-101.592-0)/52.1158
=-1.43

Inventiva's Net Cash per Share for the quarter that ended in Jun. 2024 is calculated as

Net Cash per Share (Q: Jun. 2024 )
=(Cash, Cash Equivalents, Marketable Securities-Total Liabilities-Minority Interest)/Shares Outstanding (EOP)
=(10.147-118.485-0)/52.3615
=-2.07

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Inventiva  (XPAR:IVA) Net Cash per Share Explanation

Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.


Inventiva Net Cash per Share Related Terms

Thank you for viewing the detailed overview of Inventiva's Net Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Inventiva Business Description

Traded in Other Exchanges
Address
50 rue de Dijon, Daix, FRA, 21121
Inventiva SA is a France-based biopharmaceutical company specialized in developing drugs that impact on nuclear receptors, transcription factors and epigenetic modulation. The company is focused on developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis, or NASH, a disease for which there are currently no approved therapies. The company is also involved in developing a portfolio of pre-clinical therapy programs. It operates in the segment of Service delivery and clinical stage research, notably into therapies in the areas of oncology, fibrosis, and rare diseases. All the company's operations are in France. Majority of the group's revenue is derived from its research partnerships with AbbVie and BI.